Quest Diagnostics Analysts Increase Their Forecasts After Q3 Earnings

While Quest Diagnostics raised its revenue and adjusted earnings guidance for full-year 2025, the company lowered its GAAP ...
TipRanks on MSN

Quest Diagnostics price target raised to $195 from $190 at Barclays

Barclays raised the firm’s price target on Quest Diagnostics (DGX) to $195 from $190 and keeps an Equal Weight rating on the shares post the Q3 ...
Fintel on MSN

Barclays Maintains Quest Diagnostics (DGX) Equal-Weight Recommendation

Fintel reports that on October 22, 2025, Barclays maintained coverage of Quest Diagnostics (NYSE:DGX) with a Equal-Weight ...
Business Insider

Quest Diagnostics price target raised to $198 from $190 at BofA

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares. Sentiment for Life Sciences and Diagnostic Tools and ...
Business Insider

Quest Diagnostics price target raised to $189 from $178 at Mizuho

Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $189 from $178 and keeps an Outperform rating on the shares. The firm surveyed 215 physicians over 13 specialties to gauge hospital ...
Seeking Alpha

Co-Diagnostics targets 2025 clinical evaluations for TB and HPV tests in India and South Africa

CEO Dwight Egan highlighted the development advancements of the Co-Dx PCR testing platform, including its low-cost, rapid, and easy-to-use features. The company withdrew its initial FDA 510(k) ...
Nasdaq

Bluejay Diagnostics (BJDX) Price Target Increased by 1900.00% to 61.20

The average one-year price target for Bluejay Diagnostics (NASDAQ:BJDX) has been revised to 61.20 / share. This is an increase of 1,900.00% from the prior estimate of 3.06 dated July 5, 2023. The ...